JP2021521171A5 - - Google Patents

Info

Publication number
JP2021521171A5
JP2021521171A5 JP2020555466A JP2020555466A JP2021521171A5 JP 2021521171 A5 JP2021521171 A5 JP 2021521171A5 JP 2020555466 A JP2020555466 A JP 2020555466A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2021521171 A5 JP2021521171 A5 JP 2021521171A5
Authority
JP
Japan
Prior art keywords
antibody
sugar
preparation according
item
preparation
Prior art date
Application number
JP2020555466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521171A (ja
JPWO2019198101A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IN2019/050293 external-priority patent/WO2019198101A1/en
Publication of JP2021521171A publication Critical patent/JP2021521171A/ja
Publication of JP2021521171A5 publication Critical patent/JP2021521171A5/ja
Publication of JPWO2019198101A5 publication Critical patent/JPWO2019198101A5/ja
Pending legal-status Critical Current

Links

JP2020555466A 2018-04-10 2019-04-10 治療用抗体の安定な製剤 Pending JP2021521171A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841013647 2018-04-10
IN201841013647 2018-04-10
PCT/IN2019/050293 WO2019198101A1 (en) 2018-04-10 2019-04-10 Stable formulations of therapeutic antibody

Publications (3)

Publication Number Publication Date
JP2021521171A JP2021521171A (ja) 2021-08-26
JP2021521171A5 true JP2021521171A5 (https=) 2022-04-15
JPWO2019198101A5 JPWO2019198101A5 (https=) 2022-04-15

Family

ID=68164106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555466A Pending JP2021521171A (ja) 2018-04-10 2019-04-10 治療用抗体の安定な製剤

Country Status (10)

Country Link
US (1) US12433947B2 (https=)
EP (1) EP3773696A4 (https=)
JP (1) JP2021521171A (https=)
CN (1) CN112292146A (https=)
AU (1) AU2019251453A1 (https=)
BR (1) BR112020020703A2 (https=)
CO (1) CO2020013571A2 (https=)
SG (1) SG11202009876TA (https=)
WO (1) WO2019198101A1 (https=)
ZA (1) ZA202006264B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007520A (es) 2015-12-18 2018-08-01 Astellas Pharma Inc Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
AU2019251452A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2024098180A1 (en) * 2022-11-07 2024-05-16 Wuxi Biologics (Hong Kong) Limited Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
US20240101679A1 (en) * 2020-12-09 2024-03-28 Dr. Reddy’S Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
US20240254237A1 (en) * 2021-06-04 2024-08-01 Polpharma Biologics S.A. Vedolizumab formulation
EP4717712A2 (en) * 2021-12-27 2026-04-01 Polpharma Biologics S.A. Vedolizumab formulation
KR20250120995A (ko) 2022-11-07 2025-08-11 업스트림 바이오, 인크. 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
KR101247418B1 (ko) * 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
WO2017015198A1 (en) 2015-07-17 2017-01-26 Coherus Biosciences, Inc. Stable aqeous formulations of natalizumab
US20220267449A1 (en) 2019-06-10 2022-08-25 Takeda Pharmaceutical Company Limited METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY

Similar Documents

Publication Publication Date Title
JP2021521171A5 (https=)
JP2024001364A5 (https=)
JP2021521159A5 (https=)
US10736840B2 (en) Thermally stable vaccine formulations and microneedles
JP2019536761A5 (https=)
JP2021503485A5 (https=)
RU2011127913A (ru) Составы, содержащие антитела
HRP20251316T1 (hr) Stabilne formulacije polipeptida i njihova upotreba
JP2012515221A5 (https=)
JP2014139229A5 (https=)
JP2017516848A5 (https=)
RU2016150640A (ru) Жидкая фармацевтическая композиция
JP2013521296A5 (https=)
CN101631563B (zh) 含有流感疫苗的冻干制剂及其制备方法
JP2019504086A5 (https=)
JP2019509311A5 (https=)
HRP20250830T1 (hr) Farmaceutski pripravak s niskim ph koji sadrži konstrukte protutijela koja djeluju na t-stanice
JP2017516847A5 (https=)
RU2019100887A (ru) Композиции антитела и белка
RU2013148119A (ru) Лиофилизированный препарат ботулотоксина
FI2608805T4 (fi) NEISSERIA MENINGITIDIS rLP2086 -ANTIGEENIEN STABIILEJA FORMULAATIOITA
RU2018129077A (ru) Стабильная фармацевтическая композиция
RU2019116756A (ru) Жидкая фармацевтическая композиция
JP2019512012A5 (https=)
JP2013531679A5 (https=)